Hemab Therapeutics (NASDAQ:COAG – Get Free Report) was upgraded by analysts at HC Wainwright to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.
COAG has been the subject of several other reports. Zacks Research upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Jefferies Financial Group assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price objective for the company. Evercore started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective for the company. Wedbush started coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price target for the company. Finally, The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $41.40.
Get Our Latest Stock Report on COAG
Hemab Therapeutics Trading Up 3.7%
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last issued its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.
Insider Activity
In other Hemab Therapeutics news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $48,150,000.00. Following the purchase, the director directly owned 6,149,096 shares in the company, valued at $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have bought 2,970,541 shares of company stock valued at $55,459,603.
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Recommended Stories
- Five stocks we like better than Hemab Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
